Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or… | Phase 2 | terminated | Jul 21, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02359500 | 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive… | Phase 1 | terminated | Feb 10, 2015 | Lale Kostakoglu | compound no longer available | Other (stated, no rule matched) |
| NCT01476553 | Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in…(EIPL) | N/A | terminated | Nov 22, 2011 | Universitätsmedizin Mannheim | Prematurely halted after interim data analysis | Other (stated, no rule matched) |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic… | Phase 1 | terminated | Jul 31, 2013 | OHSU Knight Cancer Institute | After enrollment of the first 3 subjects, an interim assessment was conducted. Comparing DBS… | Enrollment / accrual |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | Phase 2 | terminated | Jul 21, 2016 | OHSU Knight Cancer Institute | Drug safety concerns | Safety / toxicity |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | Phase 1 / Phase 2 | terminated | Jan 1, 2013 | Fred Hutchinson Cancer Center | A Phase I/II study (NCT01758458) is now recruiting | Enrollment / accrual |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | Phase 2 | terminated | Nov 1, 2012 | Joel Neal | Lack of efficacy | Efficacy / futility |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head… | Phase 2 | terminated | Dec 28, 2010 | National Cancer Institute (NCI) | Study treatment did not show clinical activity. | Other (stated, no rule matched) |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | Phase 2 | terminated | Oct 26, 2006 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT01729832 | Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast… | N/A | withdrawn | Nov 20, 2012 | Ohio State University Comprehensive Cancer Center | not stated | Not stated |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001… | Phase 2 | terminated | Apr 2, 2008 | Sandy Srinivas | slow accrual | Enrollment / accrual |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | Jun 28, 2010 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | Phase 2 | terminated | Nov 20, 2012 | University of Washington | Study ended early due to slow enrollment | Enrollment / accrual |
| NCT01484769 | Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells(H&N) | — | withdrawn | Dec 2, 2011 | University of Louisville | not stated | Not stated |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Feb 26, 2014 | Amsterdam UMC, location VUmc | not stated | Not stated |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma… | Phase 1 | terminated | Mar 18, 2015 | Millennium Pharmaceuticals, Inc. | The study was terminated because preliminary PK and overall clinical data demonstrated compelling… | Other (stated, no rule matched) |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | Phase 3 | terminated | Jul 29, 2011 | National Cancer Institute, Naples | lack of enrolment | Enrollment / accrual |
| NCT00127036 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | Phase 2 | terminated | Aug 5, 2005 | H. Lee Moffitt Cancer Center and Research Institute | drug now on market | Other (stated, no rule matched) |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Phase 1 | terminated | Dec 24, 2014 | Celgene | Slow enrollment and business decision. No safety concerns were identified for the study drugs. | Safety / toxicity |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple-… | Phase 2 | withdrawn | Feb 18, 2016 | Peregrine Pharmaceuticals | not stated | Not stated |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot… | Phase 2 | terminated | Jun 22, 2007 | Quynh-Thu Le | Poor accrual. | Enrollment / accrual |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable… | Phase 2 | terminated | Jul 27, 2009 | Pamela L. Kunz | Extreme toxicity of Pertuzumab and Erlotinib combination | Safety / toxicity |
| NCT00443261 | Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 | terminated | Mar 5, 2007 | University of Kansas Medical Center | Accrual problems | Enrollment / accrual |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | Phase 2 | terminated | Dec 18, 2007 | University of Pittsburgh | Bayer Healthcare is no supplying the study drug | Other (stated, no rule matched) |
| NCT00903461 | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck… | Phase 1 | terminated | May 18, 2009 | University of Pittsburgh | drug supply issues | Drug supply |
| NCT00937612 | Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk | N/A | terminated | Jul 13, 2009 | Chang Gung Memorial Hospital | Study group showed better results. Poor Accrual. | Enrollment / accrual |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of… | Phase 2 | withdrawn | Jul 16, 2012 | Imunon | not stated | Not stated |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate… | Phase 1 / Phase 2 | terminated | Apr 10, 2009 | John P. Fruehauf | Terminated due to slow accrual. | Enrollment / accrual |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | — | terminated | Jul 15, 2010 | Stanford University | accrual | Enrollment / accrual |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Phase 2 | withdrawn | Jan 27, 2014 | Weill Medical College of Cornell University | Investigator terminated due to funding issues | Investigator |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic,… | Phase 1 / Phase 2 | terminated | May 6, 2008 | Duke University | Slow accrual | Enrollment / accrual |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | Phase 3 | terminated | Dec 18, 2014 | Assistance Publique - Hôpitaux de Paris | Decision of investigator | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 3, 2017source: clinicaltrials